In many cancers, this is due to loss of function of RB itself, however, in melanoma RB is often functional, and instead aberrant activation of this pathway is predominately driven by a loss of p16INK4a and, subsequently, constitutive CDK4/6 activity (51). This evidence concerns the gene CDKN2A and melanoma.